PACE (Pathways to Antimicrobial Clinical Efficacy)
Overview
PACE (Pathways to Antimicrobial Clinical Efficacy) is a UK-based public-private partnership that provides grant funding and support to accelerate early-stage innovation in antimicrobial resistance (AMR) research and development.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oxford Drug Design | Feb 2025 | Grant | Co-investor |
| Innotive Diagnostics | Nov 2024 | Grant | Co-investor |
| Glox Therapeutics | Nov 2024 | Grant | Co-investor |
| PhalconBio GmbH | Feb 2025 | Grant | Lead |
| ArrePath | Nov 2024 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is PACE (Pathways to Antimicrobial Clinical Efficacy) based?
PACE (Pathways to Antimicrobial Clinical Efficacy) is headquartered in United Kingdom.
When was PACE (Pathways to Antimicrobial Clinical Efficacy) founded?
PACE (Pathways to Antimicrobial Clinical Efficacy) was founded in 2023.
How many portfolio companies does PACE (Pathways to Antimicrobial Clinical Efficacy) have?
PACE (Pathways to Antimicrobial Clinical Efficacy) has 9 portfolio companies in Caplight's dataset.
What are some companies in PACE (Pathways to Antimicrobial Clinical Efficacy)'s portfolio?
Portfolio companies visible on Caplight include Oxford Drug Design, Innotive Diagnostics, Glox Therapeutics, PhalconBio GmbH, ArrePath.
What was PACE (Pathways to Antimicrobial Clinical Efficacy)'s most recent investment shown here?
PACE (Pathways to Antimicrobial Clinical Efficacy)'s most recent investment in this portfolio sample was in Oxford Drug Design in 2025.
What sectors does PACE (Pathways to Antimicrobial Clinical Efficacy) focus on?
PACE (Pathways to Antimicrobial Clinical Efficacy) focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does PACE (Pathways to Antimicrobial Clinical Efficacy) focus on?
PACE (Pathways to Antimicrobial Clinical Efficacy) typically invests at the MultiStage stage.
What is PACE (Pathways to Antimicrobial Clinical Efficacy)'s AUM?
PACE (Pathways to Antimicrobial Clinical Efficacy)'s assets under management are estimated between $37.5M and $37.5M.